ZOMETA® Reduces Skeletal-Related Events From Bone Metastases In Multiple Myeloma Patients

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumor types

ZOMETA^®effectively helps to protect patients with multiple myeloma from the threat of SREs

Time to first SRE, ZOMETA vs placebo in patients with multiple myeloma⁶

ZOMETA® Reduction in Time to First SRE vs Placebo in Multiple Myeloma

ZOMETA delivered equivalent efficacy to that of pamidronate in delaying SREs (376 days vs 356 days, respectively) for patients with multiple myeloma or breast cancer in a noninferiority trial⁶

ZOMETA can delay and reduce SREs in patients with multiple myeloma and bone lesions⁶

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA®effectively helps to protect patients with multiple myeloma from the threat of SREs

ZOMETA can delay and reduce SREs in patients with multiple myeloma and bone lesions6

ZOMETA^®effectively helps to protect patients with multiple myeloma from the threat of SREs

ZOMETA can delay and reduce SREs in patients with multiple myeloma and bone lesions⁶